Meagan P O'Brien

Title: Meagan P O'Brien: Innovator in Antibody Research

Introduction

Meagan P O'Brien is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of antibody research, particularly in the treatment and prevention of viral infections and allergies. With a total of 3 patents, her work has the potential to impact public health significantly.

Latest Patents

One of her latest patents focuses on methods for treating or preventing SARS-CoV-2 infections and COVID-19 using anti-SARS-CoV-2 spike glycoprotein antibodies. This invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods feature the administration of one or more antigen-binding molecules, such as antibodies, that bind to a surface protein of SARS-CoV-2, specifically the spike protein. Another notable patent involves methods of treating allergy using anti-Bet v 1 antibodies. This disclosure provides methods for treating, preventing, or ameliorating symptoms of birch allergy or allergic disease by administering an antibody or antigen-binding fragment that binds to Bet v 1.

Career Highlights

Meagan has worked with leading companies in the biotechnology sector, including Regeneron Pharmaceuticals, Inc. and Sanofi Biotechnology. Her experience in these organizations has allowed her to collaborate with some of the brightest minds in the industry.

Collaborations

Throughout her career, Meagan has collaborated with notable colleagues, including Jennifer D Hamilton and Gary Herman. These partnerships have contributed to her innovative research and development efforts.

Conclusion

Meagan P O'Brien is a trailblazer in the field of antibody research, with a focus on addressing critical health challenges. Her patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.